PI Industries Q2 Review - CSM Drives Revenue Growth; One-Time Cost Dents Ebitda Margin: Motilal Oswal

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..Motilal Oswal Report.PI Industries Ltd.’s consolidated revenue growth was primarily driven by the custom synthesis manufacturing segment as domestic crop protection remained flat YoY. Gross margins expanded despite higher raw material costs and reduced export incentives, but were aided by the product mix. Higher other expenses dented Ebitda, weighed by-fuel and related utilities, one-time expenses pertaining to several strategic initiatives, and Covid-19 management costs. The acquisition of the active pharma ingredient and intermediates business undertaking of Ind Swift Laboratory Ltd. has been called off due to the non-fulfillment of vital pre-agreed conditions as well as the re-negotiation of pre-agreed terms. However, PI Industries remains confident of scaling up revenue from the pharma segment to 20% in the next four years..Click on the attachment to read the full report:.DISCLAIMERThis report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

PI Industries Q2 Review - CSM Drives Revenue Growth; One-Time Cost Dents Ebitda Margin: Motilal Oswal

PI Industries Q2 Review - CSM Drives Revenue Growth; One-Time Cost Dents Ebitda Margin: Motilal Oswal

Choose a plan